Evidence map›Paper›PMID 21422479›Full record

Trial reportJournal of dental research2011

Serum bone biomarkers and oral/systemic bone loss in humans.

J B Payne, J A Stoner, H-M Lee, P V Nummikoski, R A Reinhardt, L M Golub

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of dental research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00066027 (Low-Dose Doxycycline Effects on Osteopenic Bone Loss), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00066027 phase3completednot on this map

Low-Dose Doxycycline Effects on Osteopenic Bone Loss

TypeinterventionalSponsorUniversity of NebraskaRan2002 to 2005Enrolled128ConditionsPeriodontitisArms20 mg doxycycline hyclate, Placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Biochemical markers as predictors of bone remodelling in dental disorders: a narrative description of literature.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases · 2012
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

J B PayneDepartment of Surgical Specialties, University of Nebraska Medical Center College of Dentistry, Lincoln, NE 68583-0740, USA. jbpayne@unmc.edu
J A Stoner
H-M Lee
P V Nummikoski
R A Reinhardt
L M Golub

Funding

LOW-DOSE DOXYCYCLINE EFFECTS ON OSTEOPENIC BONE LOSSR01DE012872 · NIDCR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAYNE, JEFFREY BRUCE · 2001 to 2007
$3.0M
Examining multilevel associations in dental researchR03DE019805 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI STONER, JULIE A · 2010 to 2011
$308k
NIDCR NIH HHS R01 DE012872NIDCR NIH HHS R01DE012872NIDCR NIH HHS R01 DE012872-07NIDCR NIH HHS R03 DE019805NIDCR NIH HHS R03DE019805NIDCR NIH HHS R03 DE019805-01A1
6 · The paper itself

Abstract

unlabelledWe recently reported that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. We hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (BMD) changes, but also with alveolar bone changes over time. One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunctive to periodontal maintenance. Sera were analyzed for bone biomarkers. As expected, two-year changes in a serum bone biomarker were significantly associated with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025). Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I collagen (ICTP; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008), respectively. Thus, we have shown that serum bone biomarkers are associated with not only systemic BMD loss, but with alveolar bone loss as well. CLINICAL TRIAL REGISTRATION INFORMATION: Protocol registered at ClinicalTrials.gov, NCT00066027.

Indexed as

AgedAlkaline PhosphataseAlveolar Bone LossAnti-Bacterial AgentsBiomarkersBone DensityBone Density Conservation AgentsBone Diseases, MetabolicChildCollagen Type IDouble-Blind MethodDoxycyclineFemaleHumansLinear ModelsMiddle AgedAlkaline PhosphataseALPL protein, humanAnti-Bacterial AgentsBiomarkersBone Density Conservation AgentsCollagen Type Icollagen type I trimeric cross-linked peptideDoxycyclineOsteocalcinPeptides

Identifiers

PMID21422479
PMCPMC3092793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.